Category: Accesswire

Crown Coins Casino expands its social sweepstakes platform with new iOS app and invite‑only VIP tier, enhancing gameplay, licensing, and user experience.

NEW YORK CITY, NEW YORK / ACCESS Newswire / July 23, 2025 / For the third consecutive year, Crown Coins Casino has secured the top spot on CasinoTop10.net’s rankings, solidifying its position as the USA’s top real money social casino. CasinoTop10.net is a renowned authority in the iGaming space and has built its reputation due to its expert-vetted and unbiased rankings. This is thanks to its strong focus on gameplay, licensing, and overall user experience.

Crown Coins is a new casino and entrant that has taken social gaming by storm. Launched in 2023 by Sunflower Limited, Crown Coins has achieved major launch milestones in less than two years. These include the debut of a dedicated iOS app and an invite-only tier in its VIP program. Read on to discover why CasinoTop10.net has ranked Crown Coins top in the crowded sweepstakes space.

Learn more about the best social casino in the USA, Crown Coins Casino, here.

Unmatched Game Variety Through Solid Partnerships

Crown Coins has curated its game list to feature some of the best slots. Its greatest feat so far has been its partnership with software giants such as Pragmatic Play and Hacksaw Gaming. Through this partnership, Crown Coins has gained access to the industry’s top games. Thanks to this, its game catalogue consistently features top-notch graphics and interesting game mechanics.

Furthermore, the casino features hundreds of titles, outperforming competitors in the social gaming scene, who often have limited titles. The slots reign supreme, offering diverse themes and in-game bonus features. This has been a major driver of the platform’s success since more variety caters to a broader audience, thus providing an overall better experience.

Learn more about Crown Coins Casino’s game variety here.

Multiple Bonuses and Promotions

Apart from game variety, Crown Coins has remained at the forefront in delivering unmatched casino bonuses. Based on CasinoTop10.net reviews, Crown Coins’ welcome offer ranks among the top based on its value and wagering requirements.

New players can access close to 100,000 GC plus 2 SC. This no-deposit offer is available before players can make any deposit. Beyond this offer, Crown Coins has created a promotions section that has continuous offers. This includes a match-up offer available after players make their first deposit. Other offers vetted and verified by CasinoTop10.net include daily log-in bonuses, referral bonuses, social giveaways, and mystery bonuses. The wagering requirement is set at 1X, attainable even by entry-level players.

Aside from regular bonuses, Crown Coins Casino has consistently raised the bar on rewarding loyal players. The casino has a VIP program that rewards its loyal and consistent players. Each point earned adds up and unlocks a new tier, resulting in players earning exclusive rewards and bonuses. The casino raised the bar slightly this year by featuring an invite-only tier. This is the highest-ranking tier that will unlock elite treatment for loyal players. The rewards include exclusive offers such as early access to new releases, luxury gifts, and priority customer support.

Learn more about the bonuses and promotions at Crown Coins Casino here.

An Intuitive User Interface to Ease Navigation

The user interface is critical in delivering a smooth and engaging user experience. With this in mind, the product development team at Crown Coins has stayed on top of its game to tailor a user-friendly platform for its mobile and desktop versions. This is done through well-laid-out icons that are distinctively placed and have a clutter-free interface. The team has worked on an easy-to-use interface for the mobile app through features such as push notifications and an integrated VIP Club. Players can easily view their progress from the menu button. In addition, the game library is well-categorized to ensure players have a seamless time finding their ideal game.

Crown Coins has significantly emphasized pure entertainment and delivered it in the form of unmatched gameplay and numerous rewards. As a sweepstakes casino, the risks are limited; therefore, the fun comes with no financial pressure. Whether low or high staker, the purchase package has been tailored to meet all players’ needs. Furthermore, all the relevant tools are within arm’s reach in problematic gaming. Players can set session timers, deposit limits, or self-exclude. This is gaming on players’ terms, which makes Crown Coins a player’s haven.

Multiple Payment Options

Recognizing the importance of fast transactions, Crown Coins has created a list of secure payment options. This is possible through partnerships with reliable payment providers. As such, players and reviewers have reported safe and fast transactions. Players can opt for credit cards, e-wallets, and online banking options for purchase and redemption. These are instant ways to purchase gold coins, while redemption takes hours and a few days. The casino has also streamlined the payment process to ensure players have a smooth gaming experience.

Learn more about Crown Coins Casino’s banking options here.

Improved Mobile Experience

Crown Coins has adjusted accordingly to meet its players’ needs. Today, players opt to wager from their mobile devices more often than desktops. To stay on top of this trend, Crown Coins has optimized its platform for mobile gaming. Players can easily access the casino from Android and iOS browsers. Software developers have designed all the games using HTML5 technology, ensuring games load fast and smoothly. A dedicated app for iOS users was launched recently. Through tests on its overall performance and load times, CasinoTop10.net has ascertained that games on the app load perfectly on different iOS models.

An Engaging and Vibrant Community

Crown Coins has taken social interaction and entertainment to a whole new level as a high-ranking social casino. Over the years, the casino has created a vibrant community on all social media platforms. Social casinos are all about entertainment with minimal risks. This is what Crown Coins has emphasized on all its social media handles. Once players log in, the live chat is full of like-minded players big on competition and fun. In addition, reliable customer support is at the heart of all operations at Crown Coins Casino. This is made possible through their highly trained professionals and robust infrastructure designed to deliver fast, prompt, and responsive help when needed.

• Phone Support: +12015354587

• Email Support: support@crowncoinscasino.com

Disclaimer & Affiliate Disclosure

The information provided in this article is for informational and entertainment purposes only. Neither the publisher nor any syndication partners make any guarantees regarding the accuracy, completeness, or reliability of the content herein. While all efforts have been made to present up-to-date and relevant information at the time of publication, errors, omissions, and inaccuracies may occur, and no warranties are expressed or implied.

This content may reference products, services, or promotional offers from third-party entities. In some cases, the publisher may receive compensation through affiliate partnerships if readers choose to sign up or make purchases through links provided in the article. These affiliate relationships do not influence the editorial integrity of the review or ranking. All recommendations reflect the subjective opinion of the original authors and independent reviewers based on their experience and research.

No financial advice, gambling advice, or guarantees of outcomes are provided in this content. Readers are solely responsible for their own decisions and are encouraged to verify any claims directly with the official Crown Coins Casino website or its authorized representatives.

Crown Coins Casino operates as a social sweepstakes casino and does not offer traditional real-money gambling. Participation is limited to eligible jurisdictions and subject to age verification and local laws. No cash wagers or real-money betting are accepted on the platform; gameplay involves virtual currency models intended solely for recreational use.

All trademarks, images, product names, and brand references are the property of their respective owners and are used in a nominative and non-commercial context under applicable fair use standards.

By continuing to read, interact with, or share this content, the user agrees to hold the publisher, its affiliates, and any third-party distribution or syndication channels harmless from any direct or indirect liability, including those arising from typographical errors, misstatements, or reliance on content presented.

For concerns related to Crown Coins Casino or its services, readers should contact the company directly at support@crowncoinscasino.com or call 12015354587.

SOURCE: Crown Coins Casino

Related Images

View the original press release on ACCESS Newswire

“DMS’s deep expertise in financial IT environments makes them the ideal partner to help PE firms realize the full potential of AI agents in finance” – Alberto Rizzoli, CEO of V7

NEW YORK, NY / ACCESS Newswire / July 23, 2025 / V7, the platform behind V7 Go, announces a strategic partnership with DMS Technology, a New York-based IT consultancy serving private equity firms and financial institutions. This partnership is aimed at helping PE firms and their portfolio companies adopt intelligent agents to automate high-volume document workflows in due diligence, investment memo creation, fund performance analysis, and compliance reporting.

Key Benefits of the Partnership:

• Private Equity-Focused Deployment: Pre-built GenAI agents for parsing CIMs, analyzing pitch decks, summarizing NDAs, and generating investment memos – built to support M&A and fund operations.

• Faster Execution Across Portfolios: DMS will work directly with PE firms to roll out agents across target companies – cutting weeks off diligence cycles and internal reporting.

• Control and Compliance: V7 Go agents are version-controlled, auditable, and optimized for sensitive financial data – ensuring alignment with regulatory and investor expectations.

The Strength of DMS Technology

With over two decades of experience advising financial institutions and PE firms, DMS brings deep technical and operational understanding of what it takes to scale AI tools securely within finance-driven environments.

“At DMS, we’ve seen firsthand how private equity firms are seeking smarter, faster ways to manage information. Partnering with V7 allows us to bring cutting-edge AI directly into the workflows that matter most – accelerating diligence, improving accuracy, and freeing up teams to focus on strategic decisions,” said Jonathan Edwards, CEO of DMS.

Transforming Private Finance

Private equity firms will benefit from streamlined adoption paths for V7 Go agents. These AI agents are designed to analyze complex financial documents such as Confidential Information Memorandums, legal agreements, and fund reports. They automate critical tasks such as extracting key metrics, identifying risks, and structuring data. DMS Technology’s experience will help PE clients integrate generative AI tools into their due diligence and portfolio monitoring workflows.

A Shared Vision for Scalable Intelligence

As private equity firms look to AI for competitive edge, the V7-DMS partnership offers a scalable way to embed intelligence across core workflows – unlocking better decisions, faster deals, and stronger returns.

“This partnership reflects a shared commitment to innovation and operational excellence. By combining V7’s AI capabilities with our deep understanding of financial IT environments, we’re enabling PE firms to scale intelligence across their portfolios and unlock real competitive advantage,” said Jonathan Edwards.

By combining V7’s innovative technology with DMS’s understanding of financial IT environments and implementation know-how, the collaboration will help private equity firms leverage AI for better investment outcomes.

About V7:

V7 is a London-based AI company specializing in document intelligence and workflow automation. Its flagship product, V7 Go, enables teams in document-heavy industries like legal, finance, and insurance to build and deploy custom AI agents for processing complex documents and automating knowledge work. V7 focuses on delivering verifiable outputs with transparent AI logic to ensure accuracy and compliance. V7 was recently recognized in Tech Nation’s Future Fifty 2025 cohort and Sifted’s Rising 100.

About DMS Technology:

DMS Technology provides strategic business IT consulting and management to clients across various industries, with a strong focus on financial institutions and private equity. Covering North America and Europe, DMS offers enterprise-level technology advising and proactive management designed to align IT solutions with business objectives, enhance efficiency, and ensure regulatory compliance.

To arrange a demo and learn how AI agents powered by V7 Go can streamline your private equity workflows, contact Contact@dmstechnology.com at DMS Technology.

Media Contact Information:

V7:
Casimir Rajnerowicz
marketing@v7labs.com

DMS Technology:
Eric Rabinowitz
ericr@nurturemarketing.com
+1 732 421 2670

SOURCE: V7

View the original press release on ACCESS Newswire

NSPA Supports Denmark and European Countries in MQ-9B Acquisition and Sustainment

SAN DIEGO, CA / ACCESS Newswire / July 23, 2025 / Denmark and the NATO Support and Procurement Agency (NSPA) have announced the procurement of four MQ-9B SkyGuardian^® Remotely Piloted Aircraft (RPA) from General Atomics Aeronautical Systems, Inc. The purchase includes three Certified Ground Control Stations.

Denmark joins a growing list of European countries that have selected MQ-9B for its multi-domain capabilities with exceptionally long range and endurance. The platform provides pole-to-pole satellite control and de-icing capabilities to enable missions in the harsh conditions of the Arctic in support of Denmark and its NATO Allies. Additionally, MQ-9B’s in-house-developed Detect and Avoid System aids MQ-9B’s ability to fly in unsegregated airspace for domestic civilian operations, making it highly versatile for operations from Denmark.

MQ-9B recently became the first large remotely piloted aircraft to obtain a Military Type Certificate (MTC) from the UK’s Military Aviation Authority, certifying its safe operation without geographic restrictions, including over populous areas.

“It’s been a very productive year for our MQ-9B platforms,” said GA-ASI President David R. Alexander. “First, we earned MTC and now we’ve added Denmark to the U.K., Belgium, and Poland as MQ-9B customers in Europe. I believe the extensive waters of the North Sea, Norwegian Sea, and Baltic Sea of the Nordic countries make the MQ-9B a very effective tool for national maritime surveillance and security.”

MQ-9B SkyGuardian is the first and only unmanned system to offer multi-domain Intelligence, Surveillance, Reconnaissance, and Targeting (ISR&T) as an internal payload that can search the ocean’s surface and its depths in support of Fleet Operations. MQ-9B can also be fitted with a number of payloads including a maritime surveillance package with a 360-degree maritime radar and/or sonobuoy dispensing pods.

This sale was aided and supported by NSPA, which has developed a contractual framework for supporting cooperation amongst its member nations and promoting the proliferation of MQ-9B in Europe. NSPA has added MQ-9B to its portfolio of defense systems to contract on behalf of European nations, with the goal of enhancing interoperability while facilitating training and joint operations.

“This procurement demonstrates how NSPA enables efficient, effective and responsive multinational acquisitions for advanced, interoperable capabilities. We are proud to support Denmark in this strategic investment for national maritime surveillance and security,” said Ms. Stacy A. Cummings, NSPA General Manager.

About GA-ASI

General Atomics Aeronautical Systems, Inc. is the world’s foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 8 million flight hours, the Predator^® line of UAS has flown for over 30 years and includes MQ-9A Reaper^®, MQ-1C Gray Eagle^®, MQ-20 Avenger^®, and MQ-9B SkyGuardian^®/SeaGuardian^®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.

For more information, visit www.ga-asi.com.

Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.

# # #

Contact Information

GA-ASI Media Relations
asi-mediarelations@ga-asi.com
(858) 524-8101

SOURCE: General Atomics Aeronautical Systems, Inc.

Related Images

View the original press release on ACCESS Newswire

FREMONT, CA / ACCESS Newswire / July 23, 2025 / Exclusive Networks, a global leader in cybersecurity, has established a North American distribution agreement with A10 Networks that will magnify the reach of the distributor’s security and infrastructure solutions for on-premises, hybrid cloud and edge-cloud environments.

“We place a high value on organizations that can effectively support our missions in both cybersecurity and the channel, and Exclusive Networks excels in both areas,” says Phil Labas, RVP, Americas channel and alliance partners at A10 Networks. “This relationship will expand our reseller base, education and marketing abilities, and collective technical expertise, as well as support strategic use cases in security and AI across the enterprise market.”

This new arrangement allows solution providers to procure A10 Networks’ products and services in the United States and Canada through the Exclusive Networks’ growing community. A10’s specialized network, application and AI security solutions target mid-market to enterprise organizations, including global enterprises, service providers, federal agencies, and public sector institutions. The A10 Networks solutions are designed to support customers with complex networking, security, and application delivery requirements-such as DDoS protection, SSL inspection, CGNAT, NG-WAF, API and bot protection, and AI-ready high-performance load balancing.

“MSPs, VARs, solution providers and systems integrators are seeking more advanced cybersecurity tools to protect their clients and themselves from the rising threats, and our new relationship with A10 Networks will simplify that process,” says Andrew Warren, Vice President of Sales & Marketing for Exclusive Networks, North America. “This agreement is consistent with our commitment to offering the most comprehensive network, application and AI security solutions to our partners and, ultimately, their clients. We anticipate A10 Networks will bring a wealth of new sales and support opportunities to all the skilled IT and cybersecurity professionals in the Exclusive Networks community.”

Key advantages of this agreement for the community include:

• More advanced and highly comprehensive network, application and AI security capabilities

• Simplified procurement through Exclusive Networks

The addition of A10 Networks to Exclusive Networks’ line card is part of a larger initiative to expand the distributor’s capabilities and presence in North America. This includes major additions to its North American leadership team, and revitalized investments in consultative services and offerings that go beyond traditional legacy distribution offerings. The objective is to support resellers and end users in the most practical and urgent ways possible, helping them grow and thrive.

For more information or help ordering these technologies, contact your Exclusive Networks North American account management team.

About Exclusive Networks
Exclusive Networks is a global cybersecurity go-to-market specialist that provides partners and end-customers with a wide range of services and product portfolios via proven routes to market. With offices in over 45 countries and the ability to serve customers in over 170 countries, we combine a local perspective with the scale and delivery of a single global organization.

Our best-in-class vendor portfolio is carefully curated with all leading industry players. Our services range from managed security to specialist technical accreditation and training and capitalize on rapidly evolving technologies and changing business models. For more information visit https://www.exclusive-networks.com/usa/.

# # #

The A10 logo and A10 Networks are trademarks or registered trademarks of A10 Networks, Inc. in the United States and other countries. All other trademarks are the property of their respective owners.

FOR MORE INFORMATION, CONTACT:
Suzanne Mattaboni, CommCentric (on behalf of Exclusive Networks)
smattaboni@commcentric.com

SOURCE: Exclusive Networks USA

View the original press release on ACCESS Newswire

Live Coaching to Help Retirees Turn Savings into Lifetime Paychecks

JACKSONVILLE, OR / ACCESS Newswire / July 23, 2025 / Retirement income expert Cathy Mendell, founder of Theia Financial, is launching Your Next Chapter, a highly interactive live virtual coaching workshop created to guide retirees through their transition from work paychecks to retirement paychecks. With coaching workshops for the public and private retirement readiness workshops designed for employers, Your Next Chapter provides those nearing retirement with a guided path to the vital components of creating a successful retirement income plan.

The massive wave of Americans approaching retirement, who are the first to rely on 401(k)s and other defined contribution plans rather than traditional pensions, now faces a critical turning point. The shift from relying on employer-managed retirement plans to the sudden responsibility of self-managing their investments upon leaving the workforce has many retirees feeling uncertain, vulnerable to market risk, and overwhelmed as they realize the onus has been placed on them to convert their retirement assets into a reliable monthly income that they won’t outlive. With 11,200 Americans turning 65 every day through 2027, the need for guidance has never been greater.

Cathy Mendell has provided one-on-one coaching to hundreds of retirees as they transition from the accumulation phase of retirement, while working, to the decumulation phase upon retirement. With her proprietary framework, TheiaPath, she offers more than just a “probability of success”; she delivers a step-by-step process to help clients maximize their monthly retirement income and protect themselves against the financial threats of longevity, inflation, taxes, and sequence-of-returns risk in the stock market.

Through Your Next Chapter, Mendell now opens up the TheiaPath framework in the form of group coaching workshops where participants can engage, ask questions, and get answers in real-time. Here, they will define retirement goals, map out lifestyle expenses, learn about withdrawal tax strategies, discover guaranteed income options, and begin to build a retirement paycheck plan they can count on for life.

“Too many retirees are stuck hoping their savings will last, with no clear plan or income strategy. Your Next Chapter changes that. This is more than coaching, it’s a lifeline,” said Cathy Mendell, Founder of Theia Financial. “I created this program to give everyday Americans access to the information they need to begin creating a clear path to predictable income, peace of mind, and a retirement they can actually enjoy.”

About Cathy Mendell & Theia Financial:

Cathy Mendell is a nationally recognized retirement income strategist and the founder of Theia Financial. Known for her holistic and personalized approach, Cathy has helped hundreds of individuals navigate the complex transition from saving to generating reliable retirement income. Her proprietary framework, TheiaPath, offers clients a 7-step process and a written blueprint for securing a guaranteed lifetime income, enabling them to retire with clarity, security, and peace of mind.

Theia Financial is built on the belief that trust, transparency, and education are non-negotiables in financial planning. Beyond her financial work, Cathy is also deeply committed to global philanthropic efforts, including her support of the Orphanages of Kenya initiative. Her mantra reflects her mission: “Without reliable lifetime income, there is no retirement.” For more information, visit https://yournextchapterworkshop.com

Press Contact:

Veronica Welch
VEW Media
ronnie@vewpr.com
508-643-8000

SOURCE: Cathy Mendell – Theia Financial

View the original press release on ACCESS Newswire

SHELTON, CONNECTICUT / ACCESS Newswire / July 23, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, explains that the strong effectiveness of its broad-spectrum antiviral drug against all viruses that the drug NV-387 was tested against to date will drive significant valuation for its portfolio. The Company further elucidates that the MPox, Smallpox, and Measles indications of NV-387 are expected to enable rapid regulatory development towards approval and realization of early revenues from multiple pathways.

As additional indications of NV-387 have been validated in animal studies, approvals against the multiple indications of NV-387 are expected to drive increase in overall market share that the Company can achieve once the drug is approved. The costs leading up to Phase II clinical trial would be substantially common across all indications of this same drug, improving return on investment significantly.

Additionally, NV-387 should become the drug of choice to develop and stockpile for strategic pandemic preparedness and response because of its activity against most of the viruses of concern at present: Influenza, Coronaviruses, Orthopoxviruses (Smallpox and Mpox), and Measles. The Company believes that NV-387 is likely to be effective against Ebola/Marburg viruses, Hendra/Nipah viruses, and other lethal viruses as well, based on known binding of these viruses to HSPG. In addition to the USA, UK, Europe and India have established agencies to enable pandemic preparedness and response.

Approval of NV-387 against any of the currently established indications would drive its value as a strategic tool for pandemic preparedness against a multiplicity of potential threats. Pandemic preparedness is already a multi-billlion dollar market globally, and growing, as additional countries and regions seek to fortify their public health defenses against unknown viral threats. (see further below).

To this end, the Company is moving forward to open a Phase II clinical trial to evaluate effectiveness of NV-387 to treat MPox virus infections. If the trial is successful, NV-387 will be the first ever drug to be approved for MPox ^[1] . There is no effective drug for MPox at present.

Such approval will also translate to NV-387 as a currently best available option for potential smallpox therapeutics as well, based on human infection data of the smallpoxvirus-related virus MPXV , rather than animal orthopoxvirus data that FDA has currently relied upon ^[1] .

Additionally, the Company intends to file for orphan drug status for several indications of NV-387, including MPox, Smallpox, and Measles. Each orphan drug indication in itself would result in several economic benefits, in addition to increased interactions with the FDA.

We believe some of the indications of NV-387 will be eligible for Fast-Track designation, as well as for awards of Priority Review Vouchers (PRV). A PRV is a tradable instrument that has been traded at about $150 million to $250 million dollars each because the buying pharma company can apply the PRV for any one drug to expedite its own drugs in development. Thus PRVs could enable an early revenue source for the Company if awarded.

The speed with which a first indication of NV-387 can be approved is estimated to be the fastest for Mpox, Smallpox, and Measles. This is because of the specific orphan drug characteristics of these diseases in the USA. This is why the Company has prioritized these indications.

The Company is continuing its work on planning of clinical trials for what are generally considered as commercially lucrative indications that include Influenza, RSV, other respiratory viruses, as well as coronaviruses.

Viruses crossing over newly into humans from other species do so only upon acquiring significant ability to bind to HSPG, the cell-side molecule that NV-387 mimics as a decoy for the viruses ^[2] . It is highly unlikely that bioterrorism agents would be created that can drastically infect humans and yet do not bind to HSPG.

To date, pandemic preparedness has been dominated by one-drug-one-bug philosophy. With hundreds of potential biothreats, such a strategy is too expensive and would not realize a highly effective protective shield against potential pandemics.

Besides, the medical countermeasures pursued to-date for pandemic preparedness are severely lacking in that every one of them would be readily defeated by the virus as it mutates or evolves in the field. This is one lesson that has become starkly clear after the COVID-19 pandemic.

NV-387 is expected to provide a low cost option for pandemic preparedness against a multiplicity of threats, and could become an effective first response drug for practically any viral pandemic. Over 90% of viruses that can cause disease in humans are known to bind to HSPG. Our development of NV-387 suggests that most of these viruses would be susceptible to NV-387. Moreover, escape from NV-387 is highly unlikely because even as viruses mutate or evolve, they continue to bind well to HSPG as long as they are pathogenic in humans.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) ( www.nanoviricides.com ) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

^[1] Tecovirimat and Brincidofovir were approved by the US FDA for Smallpox therapeutics based on animal model data generated in animal infections by animal native orthpoxviruses. Tecovirimat failed in clinical trials of MPox. Brincidofovir caused sever drug-induced liver injury (DILI) in there of three patients given the drug in case studies, not in clinical trial.

^[2] It has been reported that highly pathogenic duck influenza viruses that lack or substantially lack HSPG binding ability do not cause significant pathology in other birds, nor in humans. They appear to use exclusively sialic acid-related receptors and yet have failed to infect other species. We believe these results require further investigation.

SOURCE: NanoViricides

View the original press release on ACCESS Newswire

CHARLOTTE, NC / ACCESS Newswire / July 23, 2025 / Zen Massage Franchising, Inc. is accelerating its expansion plans just days after a federal court decision halted the FTC’s “click-to-cancel” rule – a blow to consumer rights and a win for chains requiring contracts and memberships. In short, businesses won-but consumers lost.

This growth initiative coincides with franchise industry veteran Keith Larson taking ownership of the company, adding deep experience in franchise operations, marketing and media. Larson’s leadership marks a new chapter as the brand amplifies its signature promise: “No Contracts. No Membership Fees. No Hassles!®”.

The July 8 court decision, backed by the U.S. Chamber of Commerce and other large contract-membership driven brands, means consumers must continue to navigate complex cancellation processes-practices Zen Massage has always avoided. While other chains cling to long-term contracts, Zen Massage offers a stark contrast by giving consumers what others won’t: hassle-free access.

“Roughly 80 percent of Zen clients switched from brands that require contracts or membership fees,” said CEO Keith Larson. “These bigger brands are thrilled by the ruling – trying to protect their so-called guaranteed revenue stream at their customers’ expense. They’re fighting against what their own clients want, but we give people freedom and flexibility in their wellness experiences. We believe you can succeed by respecting your customers – not trapping them.”

Zen Massage Franchising operates eight massage and skincare centers in Cornelius and Mooresville, NC; Charleston; Las Vegas; and Kansas City. Under Larson’s direction, the company recently secured new trademarks: “No Contracts. No Membership Fees. No Hassles!®” and “No Contracts. No Membership Fees. Just Aaaah!®”.

With new markets on the horizon, the brand is launching a franchise expansion campaign with low startup fees, streamlined operations, robust marketing resources and comprehensive training-all centralized from its Cornelius, N.C.-based headquarters and training center.

Originally scheduled to take effect July 14, the FTC’s “click-to-cancel” rule was designed to make it easier for consumers to cancel contracts and simplify auto-renewal opt-outs. A federal panel vacated the rule on July 8 for procedural missteps, effectively tabling it until the FTC either appeals or reopens the process. For now, consumers remain subject to a patchwork of state-level renewal policies-leaving many caught in the fine print.

“Consumers hate contracts and are exhausted by cancellation headaches, whether it’s cellphone plans, streaming services or massage memberships,” Larson continued. “They will make different choices once they’re given the chance.”

The FTC has not indicated whether it will appeal or reintroduce the rule, leaving both consumers and businesses navigating inconsistent renewal laws across states.

Larson’s history with Zen Massage spans more than a decade. He first joined in 2013 through a system rebranding initiative led by his advertising agency, became a minority investor in 2018, a franchisee in 2019, was named CEO in 2021-culminating in his full acquisition of the company in 2025. Larson spent 13 years with McDonald’s Corp., rising to regional director of franchised operations, then served as senior vice president at Moroch, one of McDonald’s top ad agencies.

About Zen Massage Franchising, Inc.
Zen Massage Franchising, Inc. offers a competitive advantage for consumers and franchisees in the growing wellness sector. For consumers, there are no binding contracts or membership fees. Instead, the company provides everyday value pricing and a straightforward experience. Franchisees benefit from lower startup fees, efficient center operations, robust support, and significant opportunities for growth. The company supports franchisees with comprehensive training, operational guidance, and marketing resources from its Cornelius, N.C.-based headquarters and training center.

Franchise offerings are only made through the Zen Massage Franchise Disclosure Document (FDD) and process. For franchise information, contact Larson at klarson@zenmassageusa.com or (704) 947-9162, or visit zenmassageusa.com/franchise-information/.

Contact:
Cindy Stranad
919-810-7272
Cindy@articulon.com

SOURCE: Zen Massage Franchising, Inc.

View the original press release on ACCESS Newswire

By joining the RPOA community of leaders, LHH is taking a leading and active role in shaping the future of RPO and establishing the practice as a strategic engine for organizational agility.

NEW YORK CITY, NY / ACCESS Newswire / July 23, 2025 / LHH, a global integrated professional talent solutions provider and global business unit of the Adecco Group, today announced its Gold Membership with the Recruitment Process Outsourcing Association (RPOA). This move underscores LHH’s commitment to advancing the RPO industry and marks a significant step in LHH‘s strategic expansion within the RPO sector, with its full offering centralized by The Adecco Group under LHH earlier this year.

“Now that our RPO offering is fully integrated as LHH RPO, our partnership with RPOA is critical to ensure we are actively guiding the strategic evolution and new standard of RPO globally,” shared Serge Shine, Global Head of LHH RPO. “LHH is the only provider that combines flexible RPO solutions with development and career transition services, helping organizations solve talent challenges holistically. We help organizations think bigger than just filling jobs. By connecting hiring to their larger talent priorities, we make every recruitment decision count. This comprehensive approach empowers our clients to hire smarter and pivot faster.”

“That’s not the only thing that sets LHH RPO apart.” Adds Alex Ridder, LHH RPO Head of Client Partnerships: “Talent acquisition isn’t happening in isolation anymore, that’s why we designed LHH’s RPO offering to be highly adaptable. Whether it’s scaling recruitment quickly in competitive markets, integrating new hiring tech without disrupting teams, or building talent pipelines for hard-to-fill roles, we help people make work meaningful while helping to tackle the tough challenges together. Our approach combines innovation and human centricity, with exceptional care, to deliver results that matter.”

With 400+ experts across five continents, LHH RPO works with clients across various industries to develop and optimize their RPO strategies through a comprehensive and flexible suite of RPO solutions, backed by global reach and local knowledge, to help drive cost efficiency and transform organizations across the entire talent lifecycle.

Earlier this year, LHH RPO was named a ‘Major Contender’ in Everest Group’s 2025 PEAK Matrix® for Global RPO Services, a milestone moment and a reflection of the impact LHH brings in rethinking talent solutions.

“LHH joining the RPOA network supports our mission of fostering a collaborative community where RPO leaders can gather and share knowledge, transforming the future of the workforce collectively,” said Lamees Abourahma, RPOA CEO. “LHH RPO provides value to our members addressing the challenges and needs of the RPO ecosystem with unique perspectives.” She added, “We’re thrilled to recognize and support LHH’s RPO integration and market expansion and look forward to welcoming their experts to engage, learn and contribute to the evolution of the RPO industry. This is what the RPOA is all about, empowering leaders and advancing the profession.”

For more information on LHH RPO’s offerings, visit LHH’s Guide to Recruitment Process Outsourcing or contact LHH RPO.

###

About LHH

LHH empowers professionals and organizations to achieve bold ambitions and secure lasting impact through unique advisory services and professional talent solutions.

LHH’s full suite of offerings connects solutions that are traditionally siloed, making LHH a single talent partner for organizations. In a rapidly evolving landscape with complex challenges, we create value across the entire professional talent journey. From hiring great people, developing skills and nurturing leaders, to advancing individuals to the next stage of their careers, LHH makes talent a competitive edge.

We believe the future of work lies at the intersection of exceptional human care and innovation. Powered by science, technology, and proprietary data analytics, LHH’s approach is crafted to align with business strategies and cultures, delivering powerful, sustainable, and measurable impact.

LHH has a team of over 12,000 professionals, across 60+ countries, and more than 50 years of experience. As part of the Adecco Group, we bring together global excellence, local knowledge and centralized coordination for thousands of companies and millions of people worldwide.

Recruitment. Development. Career Transition.
LHH. A beautiful working world.

To learn more about LHH, visit: lhh.com.

About RPOA

The Recruitment Process Outsourcing Association (RPOA) is a member-driven, mission-driven organization committed to advancing, elevating, and promoting recruitment process outsourcing as a strategic talent solution. We strive to nurture a collaborative community, create thought leadership, and educate the marketplace about recruitment process outsourcing. Learn more at https://www.rpoassociation.org/

Media Contacts
LHH Public Relations
PR@lhh.com

RPOA
Lamees Abourahma, CEO
lamees@rpoassociation.org

The Adecco Group’s RPO business was consolidated under LHH in January 2025.

SOURCE: LHH

View the original press release on ACCESS Newswire

SOLO™’s Non-Proliferation Approach Aligns with U.S. NRC’s Proposed Licensing Framework Criteria for Low Risk, Proliferation-Resistant Micro Modular Reactors

NEW YORK, NY AND AUSTIN, TX / ACCESS Newswire / July 23, 2025 / Terra Innovatum Srl (“Terra Innovatum,” or the “Company”), a developer of micro-modular nuclear reactors, and GSR III Acquisition Corp. (NASDAQ:GSRT), a publicly traded special purpose acquisition company, today issued the following statement in support of the U.S. Nuclear Regulatory Commission’s (“NRC”) long-term vision for micro-modular reactor licensing, following the NRC’s public meetings on July 17-18, 2025:

“We are encouraged by the NRC’s recent public dialogue and their proposed rulemaking regarding future streamlined licensing for micro-modular and other low risk reactors. In particular, we support the NRC’s introduction of limits on the type and quantity of proliferation materials – or ‘Special Nuclear Materials’ (SNM) such as uranium or plutonium – in its proposed fundamental entry criteria, which further validates and aligns with SOLO^TM‘s Safeguards by Design approach.

In Picture: A rendering of the SOLO™ reactor seamlessly integrated within a commercial real estate setting.

From the earliest stages of development in 2018, we conceived our micro-modular reactor with a clear global mission: to deliver a safe, low risk, and non-proliferant nuclear energy solution suitable for deployment in diverse environments around the world. Recognizing the unique challenges associated with the use of SNM, we emphasized proliferation resistance not as an afterthought, but as a core design principle.

Our reactor has been embedded with safeguards which aim to limit unauthorized access, diversion, or repurposing of fissile materials and align with guidance from the International Atomic Energy Agency and Department of Energy.

SOLO^TM‘s compact, sealed core design, limits SNM while incorporating a real-time core measurement to prevent the misuse of these materials. Additionally, our decision to use standard Low Enriched Uranium fuel supports international non-proliferation objectives while leveraging existing fuel infrastructure and licensing precedents.

We commend the NRC for its transparent, inclusive approach to rulemaking and look forward to participating in the formal comment process. Terra Innovatum remains committed to working with domestic and international stakeholders to advance the responsible deployment of micro-modular reactors – and to ensuring that designs like SOLO^TM continue to lead the way.”

ABOUT TERRA INNOVATUM & SOLO^TM

Terra Innovatum’s mission is to make nuclear power accessible. We deliver simple and safe micro-reactor solutions that are scalable, affordable and deployable anywhere 1 MWe at a time.

Terra Innovatum is a pioneering force in the energy sector, dedicated to delivering innovative and sustainable power solutions. Terra Innovatum plans to leverage cutting-edge nuclear technology through the SOLO™ Micro-Modular Reactor (SMR™) to provide efficient, safe, and environmentally conscious energy. With a mission to address global energy shortages, Terra Innovatum combines extensive expertise in nuclear industry design, manufacturing, and installation licensing to offer disruptive energy solutions. Committed to propelling technological advancements, Terra Innovatum and SOLO™ are dedicated to fostering prosperity and sustainability for humankind.

It is anticipated that SOLO™ will be available globally within the next three years. Conceptualized in 2018 and engineered over six years by experts in nuclear safety, licensing, innovation, and R&D, SOLO™ addresses pressing global energy demands with a market-ready solution. Built from readily available commercial off-the-shelf components, the proven licensing path for SOLO™ enables rapid deployment and minimizes supply chain risks, ensuring final cost predictability. Designed to adapt with evolving fuel options, SOLO™ supports both LEU+ and HALEU, offering a platform ready to transition to future fuel supplies.

SOLO™ will offer a wide range of versatile applications, providing CO2-free, behind-the-meter, and off-grid power solutions for data centers, mini-grids serving remote towns and villages, and large-scale industrial operations in hard-to-abate sectors like cement production, oil and gas, steel manufacturing, and mining. It also has the ability to supply heat for industrial applications and other specialized processes, including water treatment, desalination and co-generation. Thanks to its modular design, SOLO™ can easily scale to deliver up to 1GW or more of CO2-free power with a minimal footprint, making it an ideal solution for rapidly replacing fossil fuel-based thermal plants. Beyond electricity and heat generation, SOLO™ can also contribute to critical applications in the medical sector by producing radioisotopes essential for oncology research and cancer treatment.

To learn more, visit: www.terrainnovatum.com.

CONTACTS

Giordano Morichi
Partner, Chief Business Development Officer & Investor Relations
Terra Innovatum Srl
E: g.morichi@terrainnovatum.com
W: www.terrainnovatum.com

Nicholas Hresko-Staab
Vice President
Investor & Media Relations
Alliance Advisors IR
E: TerraIR@allianceadvisors.com

IMPORTANT INFORMATION FOR SHAREHOLDERS

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or constitute a solicitation of any vote or approval.

In connection with the business combination, a Dutch public limited liability company (“Pubco”), GSR III Acquisition Corp. (“GSRT”) and Terra Innovatum s.r.l. (“Terra Innovatum” and, together with GSR III and Pubco, the “Registrant Parties”) have filed with the SEC a registration statement on Form S-4 (the “Registration Statement”), which includes a preliminary prospectus of Pubco relating to the offer of securities to be issued in connection with the business combination, and a preliminary proxy statement of GSRT to be distributed to holders of GSRT’s ordinary shares in connection with GSRT’s solicitation of proxies for a vote by GSRT’s shareholders with respect to the Business Combination and other matters described in the Registration Statement. The Registrant Parties also plan to file other documents with the SEC regarding the business combination. After the Registration Statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to the shareholders of GSRT. INVESTORS OF THE REGISTRANT PARTIES ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS CONTAINED THEREIN (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND ALL OTHER DOCUMENTS RELATING TO THE BUSINESS COMBINATION THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION.

Investors will be able to obtain free copies of the proxy statement/prospectus and other documents containing important information about the Registrant Parties once such documents are filed with the SEC, through the website maintained by the SEC at http://www.sec.gov. In addition, the documents filed by GSRT may be obtained free of charge by written request to GSRT at 5900 Balcones Drive, Suite 100, Austin TX 78731.

PARTICIPANTS IN THE SOLICITATION

Each of the Registrant Parties, and their respective directors and executive officers, may be considered participants in the solicitation of proxies with respect to the potential transaction described in this communication under the rules of the SEC. Information about the directors and executive officers of GSRT is set forth in GSRT’s filings with the SEC. Information regarding other persons who may, under the rules of the SEC, be deemed participants in the solicitation of the shareholders in connection with the potential transaction and a description of their direct and indirect interests will be set forth in the Registration Statement (and will be included in the proxy statement/prospectus) and other relevant documents when they are filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

FORWARD LOOKING STATEMENTS

The statements contained in this press release that are not purely historical are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding our expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on GSRT and the other Registrant Parties. There can be no assurance that future developments affecting GSRT and the other Registrant Parties will be those that we have anticipated. These forward-looking statements speak only as of the date this press release is delivered and involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreements with respect to the Business Combination; (2) the outcome of any legal proceedings that may be instituted against GSRT, any of the Registrant Parties, the combined company or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (3) the inability to complete the Business Combination due to the failure to obtain approval of the shareholders of GSRT or the SEC’s declaration of the effectiveness of the Registration Statement (which will include the proxy statement/prospectus contained therein) to be filed by the Registrant Parties or to satisfy other conditions to closing; (4) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (5) the ability of Pubco to meet stock exchange listing standards following the consummation of the Business Combination; (6) the risk that the Business Combination disrupts current plans and operations of Terra Innovatum as a result of the announcement and consummation of the Business Combination; (7) the ability to recognize the anticipated benefits of the Business Combination,

which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (8) costs related to the Business Combination, including the reorganization described in the business combination agreement; (9) changes in applicable laws or regulations; (10) the possibility that the Registrant Parties or the combined company may be adversely affected by other economic, business, and/or competitive factors; (11) the amount of redemption requests made by GSRT shareholders and (12) other risk factors described herein as well as the risk factors and uncertainties described in the Form S-4 and GSRT’s other filings with the SEC, as well as any further risks and uncertainties to be contained in the proxy statement/prospectus filed after the date hereof. In addition, there may be additional risks that neither GSRT nor any of the other Registrant Parties presently know, or that GSRT or the other Registrant Parties currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made.

None of GSRT, the other Registrant Parties, or any of their respective affiliates, officers, employees or agents, makes any representation or warranty, either express or implied, in relation to the fairness, reasonableness, adequacy, accuracy, completeness or reliability of the information, statements or opinions, whichever their source, contained in this press release or any oral information provided in connection herewith, or any data it generates and accept no responsibility, obligation or liability (whether direct or indirect, in contract, tort or otherwise) in relation to any of such information. GSRT, the other Registrant Parties and their respective affiliates, officers, employees and agents further expressly disclaim any and all liability relating to or resulting from the use of this press release and any errors therein or omissions therefrom. Further, the information contained herein is preliminary, is provided for discussion purposes only, is only a summary of key information, is not complete and is subject to change without notice.

In addition, the information contained in this press release is provided as of the date hereof and may change, and neither GSRT nor the other Registrant Parties undertakes any obligation to

update or revise any forward-looking statements, whether as a result of new information, inaccuracies, future events or otherwise, except as may be required under applicable securities laws.

SOURCE: TERRA INNOVATUM SRL

View the original press release on ACCESS Newswire

SIOUX FALLS, SD / ACCESS Newswire / July 23, 2025 / Avel eCare, a leading provider of telemedicine services in the United States, today announced the appointment of Martainn Lenhardt as Chief Financial Officer (CFO). Lenhardt brings over 20 years of healthcare finance experience to the role, where he will oversee Avel’s financial strategy, operations, and performance during a pivotal era of innovation and nationwide expansion.

Lenhardt joins Avel eCare following his tenure as VP of Finance at Lyric and senior leadership roles at Change Healthcare, where he managed a $480 million business unit and was instrumental in driving growth and improving margins. He is widely recognized for his expertise in strategic growth, mergers and acquisitions, and optimizing global operations. His ability to turn complexity into opportunity and build agile, purpose-driven teams will be instrumental in advancing Avel’s mission.

“Avel eCare is transforming how healthcare is delivered across the country,” said Lenhardt. “It’s an honor to join this team and help scale a model that brings high-quality, virtual care to every corner of the nation.”

This appointment comes at a time of unprecedented momentum for Avel eCare. In the past two years alone, Avel has launched new service lines, secured exclusive partnerships with organizations like Amwell and Cibolo Health, and expanded services to more than 46 states. The company continues to innovate with in-ambulance telehealth, ICU solutions, and programs that support EMS, law enforcement, and correctional health, making care more accessible, cost-effective, and consistent, especially in rural and underserved areas.

The new CFO joins an accomplished executive team committed to advancing healthcare access and outcomes across the country. Avel’s leadership includes:

• Doug Duskin – Chief Executive Officer

• Don Yish – Chief Revenue Officer

• Jay Weems – Chief Operations Officer

• Kelly Rhone, MD – Chief Medical Officer

• Robert Spurlock – Chief Information Officer

About Avel eCare
Avel eCare is a national leader in technology-enabled clinical services delivered through telemedicine, offering provider-to-provider virtual care solutions that expand clinical capacity and improve outcomes across the healthcare industry. With more than 30 years of innovation, Avel’s board-certified clinicians partner with hospitals, clinics, long-term care facilities, schools, EMS agencies, and correctional health systems nationwide to bring high-quality care to patients when and where it’s needed most. Learn more at: www.avelecare.com

Media Contact:
Jessica Gaikowski
Avel eCare
media@avelecare.com

SOURCE: Avel eCare

View the original press release on ACCESS Newswire